Elevated plasma soluble CD14 and skewed CD16+ monocyte distribution persist despite normalisation of soluble CD163 and CXCL10 by effective HIV therapy: A changing paradigm for routine HIV laboratory monitoring?

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Castley, Alison ^a,b   Berry, Cassandra ^a   French, Martyn ^b,c   Fernandez, Sonia ^c   Krueger, Romano ^b   Nolan, David ^a,b  

^a MURDOCH UNIVERSITY   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; CD45 ANTIGEN; CD64 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; SOLUBLE CD14 ANTIGEN; SOLUBLE CD163 ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; FC RECEPTOR; LEUKOCYTE ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIVIRAL THERAPY; ARTICLE; BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PHENOTYPE; PROGNOSIS; VIRUS LOAD; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; GENETICS; HIV INFECTIONS; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CASE-CONTROL STUDIES; CHEMOKINE CXCL10; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, CELL SURFACE; RECEPTORS, IGG;

EID: 84920143583     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115226     Document Type: Article

References (34)

1. Ancuta P, Liu KY, Misra V, Wacleche VS, Gosselin A, et al. (2009) Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets. BMC Genomics 10: 403.
2. Zawada AM1, Rogacev KS, Rotter B, Winter P, Marell RR, et al. (2011) SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 118:e50-61.
3. Ancuta P, Rao R, Moses A, Mehle A, Shaw SK, et al. (2003) Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 197: 1701-1707.
4. Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, et al. (2007) The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 178: 6581-6589.
5. Lawrence P, Portran D, Terrasse R, Palle S, Olivier T, et al. (2012) Selective transmigration of monocyte-associated HIV-1 across a human cervical monolayer and its modulation by seminal plasma. AIDS 26: 785-96.
6. Williams DW, Eugenin EA, Calderon TM, Berman JW (2012) Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol 91: 401-415.
7. Rogacev KS, Cremers B, Zawada AM, Seiler S, Binder N, et al. (2012) CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 60: 1512-1520.
8. Funderburg NT, Zidar DA, Shive C, Lioi A, Mudd J, et al. (2012) Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 120: 4599-4608.
9. Ulrich C, Heine GH, Seibert E, Fliser D, Girndt M (2010) Circulating monocyte subpopulations with high expression of angiotensin-converting enzyme predict mortality in patients with end-stage renal disease. Nephrol Dial Transplant 25: 2265-2272.
10. Fischer-Smith T, Tedaldi EM, Rappaport J (2008) CD163/CD16 coexpression by circulating monocytes/macrophages in HIV: potential biomarkers for HIV infection and AIDS progression. AIDS Res Hum Retroviruses 24: 417-421.
11. Tippett E, Cheng WJ, Westhorpe C, Cameron PU, Brew BJ, et al. (2011) Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One 6:e19968.
12. Li Y, Lee PY, Kellner ES, Paulus M, Switanek J, et al. (2010) Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther 12: R90.
13. Holl V, Hemmerter S, Burrer R, Schmidt S, Bohbot A, et al. (2004) Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J Immunol 173: 6274-83.
14. Sandler NG, Wand H, Roque A, Law M, Nason MC, et al. (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203: 780-790.
15. Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, et al. (2012) VACS Project Team. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 54: 984-94.
16. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, et al. (2012) Arterial inflammation in patients with HIV. JAMA 308: 379-86.
17. Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, et al. (2011) Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis 204: 154-63.
18. Simmons RP, Scully EP, Groden EE, Arnold KB, Chang JJ, et al. (2013) HIV-1 infection induces strong production of CXCL10 through TLR7/9-dependent pathways. AIDS 27: 2505-17.
19. Hattab S, Guihot A, Guiguet M, Fourati S, Carcelain G, et al. (2014) Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. BMC Infect Dis 14: 122.
20. Gale HB, Gitterman SR, Hoffman HJ, Gordin FM, Benator DA, et al. (2013) Is frequent CD4+ Tlymphocyte count monitoring necessary for persons with counts $300 cells/mL and HIV-1 suppression? Clin Infect Dis 56: 1340-3.
21. Parihar A, Eubank TD, Doseff AI (2010) Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death. J Innate Immun 2: 204-15.
22. Méndez-Lagares G, Romero-Sánchez MC, Ruiz-Mateos E, Genebat M, Ferrando-Martínez S, et al. (2013) Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14. J Infect Dis 207: 1221-5.
23. Chevalier MF, Petitjean G, Dunyach-Rémy C, Didier C, Girard PM, et al. (2013) The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog 9:e1003453.
24. Kamat A, Misra V, Cassol E, Ancuta P, Yan Z, et al. (2012) A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One 7:e30881.
25. Reiner AP, Lange EM, Jenny NS, Chaves PH, Ellis J, et al. (2013) Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler Thromb Vasc Biol 33: 158-64.
26. Merlini E1, Luzi K, Suardi E, Barassi A, Cerrone M, et al. (2012) T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis. PLoS One 7:e46073.
27. Liovat AS, Rey-Cuillé MA, Lécuroux C, Jacquelin B, Girault I, et al. (2012) Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One 7:e46143.
28. Jude C, Dejica D, Samasca G, Balacescu L, Balacescu O (2013) Soluble CD163 serum levels are elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis. Rheumatol Int 33: 1031-7.
29. Sax PE (2013) Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care? Clin Infect Dis 56: 1344-6.
30. Lake J, McComsey G, Hulgan T, Wanke C, Mangili A, et al. (2014) Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial. HIV Med Feb 10. In press.
31. Romero-Sánchez MC, Machmach K, Gonzalez-Serna A, Genebat M, Pulido I, et al. (2012) Effect of maraviroc on HIV disease progression-related biomarkers. Antimicrob Agents Chemother 56: 5858-64.
32. Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, et al. (2014) Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis 58: 588-95.
33. Kasang C1, Ulmer A, Donhauser N, Schmidt B, Stich A, et al. (2012) HIV patients treated with lowdose prednisolone exhibit lower immune activation than untreated patients. BMC Infect Dis 12: 14.
34. Sereti I, Estes JD, Thompson WL, Morcock DR, Fischl MA, et al. (2014) Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog 10:e1003890.